Opioid use disorder is a chronic relapsing substance use disorder involving compulsive opioid use despite harmful consequences, with elevated risk of overdose, infectious complications, and mortality.
Eli Lilly has launched two Phase 2 trials for brenipatide (LY3537031): RENEW-Op-1 for opioid use disorder and RENEW-Scz-1 for schizophrenia. Both are randomized, double-blind, placebo-controlled studies that are not yet recruiting as of February 2026.
Adial Pharmaceuticals completed demonstration batch production for AD04, meeting prespecified specifications and matching the prior Phase 2 dissolution profile. The step enables clinical and registration batch production for the planned Phase 3 trial.
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Eli Lilly launched the monthly Zepbound KwikPen for obesity treatment and initiated a Phase 2 trial for opioid use disorder, while Gilead Sciences agreed to acquire Arcellx for $7.8 billion to expand its cell therapy portfolio.
Recent studies reveal significant barriers in accessing mental health care for children and maternal health services, with nearly 25% of children's mental health needs going unmet and abortion restrictions linked to increased maternal deaths.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602335 |
Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants and Onset and Duration of μ-Opioid Receptor Blockade by MCAM in Healthy, Adult, Opioid-Experienced Participants |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07602218 |
Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 2 |
NOT_YET_RECRUITING | NA |
| NCT07600307 |
Evaluating a Digital Toolkit for IPV |
NOT_YET_RECRUITING | NA |
| NCT07594717 |
Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder |
RECRUITING | |
| NCT07569211 |
Simplified HCV Integrated Management Model in Methadone Clinics in Ukraine |
COMPLETED | NA |
| NCT07568847 |
Improving Hospital-To-Methadone Clinic Connection Using Implementation Support for Patients With Opioid Use Disorder |
NOT_YET_RECRUITING | NA |
| NCT07549126 |
Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 1 |
RECRUITING | NA |
| NCT07546396 |
Methadone Rapid Restart |
NOT_YET_RECRUITING | PHASE4 |
| NCT07541417 |
Building Retention and Initiation Through Delivery of Peer-Guided Evidence-Based Practices |
RECRUITING | NA |
| NCT07524738 |
Telemedicine XR-B for Individuals in Jail |
ACTIVE_NOT_RECRUITING | PHASE3 |
